Vireo Growth Inc · CSE:VREO
Vireo Growth — Vireo Health — Q4 2019 Earnings Presentation
13 slides from Vireo Growth's earnings presentation, May 14, 2020
Slide 1: Q4 2019 Earnings Conference Call
“We are building the cannabis company of the future by bringing the best of science, medicine and engineering to the cannabis industry.” Q4 2019 Earnings Conference Call May 14, 2020 - Kyle Kingsley, M.D. CNSX: VREO OTCQX: VREOF Founder & CEO
Slide 2: Disclaimer
Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This document includes information, statements, beliefs and opinions which are forward- looking, and which reflect current estimates, expectations and projections about future events, referred to herein and which constitute “forward-l
Slide 3: Today's Presenters
Today’s Presenters Kyle Kingsley, M.D. Founder & Chief Executive Officer Dial-in & Webcast Details: Dial-ins: 866-211-3165 (Toll-Free) B647-689-6580 (International) .BID 3986853 Shaun Nugent Chief Financial Officer Webcast Link: https://event.on24.com/wcc/r/2152387/64A B320B954CBA60231E21685CE46A04
Slide 4: COVID-19 Update
COVID-19 Update • Subsequent to December 31, 2019, there was a global outbreak of a new strain of coronavirus, COVID-19. The global and domestic response to the COVID-19 pandemic continues to rapidly evolve. • The Company has taken a proactive approach to protection of its customers and team members
Slide 5: Full Year 2019 Highlights
Full Year 2019 Highlights • The Company completed five acquisitions during the year and generated operating revenue in seven states: Arizona, Maryland, Minnesota, New Mexico, New York, Ohio, and Pennsylvania. Total revenue for fiscal year 2019 increased 62 percent to $30.0 million versus fiscal 2018
Slide 6: Key Fourth Quarter and Full Year 2019 Financial Metrics
Key Fourth Quarter and Full Year 2019 Financial Metrics Three Months Ended Twelve Months Ended December 31, December 31, $ in millions, except per share data 2019 2018 Variance 2019 2018 Variance Revenue $9.0 $5.6 $3.4 $30.0 $18.5 $11.5 Gross Profit (Before Fair Value Adjustments) $1.7 $1.8 ($0.1) $
Slide 7: Fiscal Year 2019 Performance
Fiscal Year 2019 Performance • Total revenue in fiscal year 2019 increased 62 percent year-over-year to $30.0 million. • Growth was driven by increasing demand and patient counts across most markets, continued wholesale market growth, and contributions from acquired entities in Arizona and New Mexic
Slide 8: Fourth Quarter 2019 Performance
Fourth Quarter 2019 Performance • Total revenue for the fourth quarter of 2019 increased 60 percent year-over-year to $9.0 million. • Revenue growth was driven by increasing demand and patient counts across most markets, continued wholesale market growth, and contributions from acquired entities in
Slide 9: Outlook
Outlook • Vireo’s long-term performance will depend largely upon federal and state legislative changes. As a result, the Company does not believe it is prudent to provide commentary regarding its expected financial performance for future fiscal years at this time. • However, the Company did today an
Slide 10: Slide 10
Slide 11: Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) || 11
Slide 12: Consolidated Statements of Financial Position
Consolidated Statements of Financial Position || 12
Slide 13: Reconciliation of IFRS to Non-IFRS Financial Measures
Reconciliation of IFRS to Non-IFRS Financial Measures Three Months Ended Twelve Months Ended December 31, December 31, 2019 2018 2019 2018 Net loss $ (37,125,766) $ (1,182,621) $ (57,010,486) $ (3,077,353) Net fair value adjustments (3,344,130) (3,608,572) (2,639,663) (7,844,612) Listing expense 66,